Greenhaven Bets Over $143 Million on a Turnaround at Medical Devices Leader Baxter

Greenhaven Associates has established a new position in Baxter International (BAX), purchasing approximately 6.29 million shares valued at $143.19 million, which constitutes 2.77% of Greenhaven's reportable equity holdings. This significant investment occurs despite Baxter's substantial underperformance, with shares down 49.1% over the past year due to challenges including slow revenue growth and increased debt. The move suggests Greenhaven's confidence in a potential turnaround driven by new CEO Andrew Hider's strategy to strengthen the balance sheet, target 3x net leverage by 2026, and reduce dividends to boost cash flow, with BAX currently trading at 9.3x forward earnings.

Analysis

Greenhaven Associates has established a new position in Baxter International (BAX), acquiring 6,288,349 shares for approximately $143.19 million, representing 2.77% of Greenhaven's $5.17 billion reportable equity holdings as of September 30, 2025. This significant institutional investment comes despite BAX's substantial underperformance, with shares down 49.1% over the past year and 78.14% over five years, significantly trailing the S&P 500. The transaction value was estimated using quarterly average pricing, with BAX trading at $18.21 on November 3, 2025.

The investment suggests Greenhaven's confidence in a potential turnaround for Baxter, a global healthcare company with a diversified portfolio including dialysis therapies and medical devices. Baxter's historical underperformance is attributed to slow revenue growth, contracting margins, increased debt from acquisitions, and manufacturing disruptions. However, new CEO Andrew Hider is prioritizing balance sheet strengthening, targeting a three-times net leverage by end of 2026, and reducing dividends to save over $300 million annually.

Baxter is currently trading at 9.3 times forward earnings, which the article notes as reasonable in the current market environment. This valuation, combined with management's strategic initiatives, could improve investor sentiment if goals are achieved. While Greenhaven's purchase does not fundamentally alter Baxter's outlook, it signals a notable institutional belief in the company's recovery potential.

The company's diversified offerings and established distribution channels provide a competitive foundation, but successful execution of the new strategy is paramount. The market impact is mildly positive, reflecting a speculative tone around the potential turnaround.

Key Decisions for Investors

• Monitor Baxter's progress on its strategic initiatives, specifically the balance sheet strengthening and net leverage target of 3x by end of 2026, as these are critical for improving investor sentiment.
• Evaluate the impact of the $300 million annual cash flow savings from dividend reductions on the company's financial flexibility and reinvestment capabilities.
• Consider Baxter's current valuation of 9.3x forward earnings in the context of its turnaround potential, recognizing that Greenhaven's new position suggests a belief in future recovery despite past underperformance.